INCB57643 / Incyte 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   8 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
INCB57643 / Incyte
NCT06619522: A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Not yet recruiting
2
30
US
Ruxolitinib, INCB57643
M.D. Anderson Cancer Center
Myelofibrosis
04/27
04/29
LIMBER, NCT04279847: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Jul 2023 - Dec 2023: Data from LIMBER trial in combination with ruxolitinib for myelofibrosis
Checkmark Data from LIMBER trial for myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from LIMBER trial for myelofibrosis at ASH 2022
Recruiting
1
216
Europe, Canada, Japan, US
INCB057643, Ruxolitinib
Incyte Corporation
Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
11/24
12/24

Download Options